Fri, January 28, 2022
Thu, January 27, 2022
Wed, January 26, 2022
Tue, January 25, 2022
Mon, January 24, 2022
Sun, January 23, 2022
Sat, January 22, 2022
Fri, January 21, 2022
Thu, January 20, 2022

Bradley Canino Upgraded (BPMC) to Strong Buy and Decreased Target to $95 on, Jan 25th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. and-decreased-target-to-95-on-jan-25th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Bradley Canino of Stifel, Upgraded "Blueprint Medicines Corporation" (BPMC) to Strong Buy and Decreased Target from $120 to $95 on, Jan 25th, 2022.

Bradley has made no other calls on BPMC in the last 4 months.



There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 1 agrees with Bradley's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $111 on, Friday, October 29th, 2021


These are the ratings of the 3 analyists that currently disagree with Bradley


  • Andrew Berens of "SVB Leerink" Maintained at Buy with Decreased Target to $120 on, Wednesday, January 12th, 2022
  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Monday, January 3rd, 2022
  • Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $133 on, Wednesday, November 10th, 2021

Publication Contributing Sources